XBIT
XBiotech Inc.2.4500
-0.0800-3.16%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
74.69MP/E (TTM)
-Basic EPS (TTM)
-0.95Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Annual meeting approvals secured
XBiotech's stockholders overwhelmingly approved all proposals at the August 29, 2025 annual meeting, electing John Simard, Thomas Kündig, Craig Rademaker, Tevi D. Troy, and David Soffer to the board with over 90% support each. They ratified Whitley Penn LLP as auditors for 2025, endorsed executive compensation on an advisory basis, and greenlit the 2025 Equity Incentive Plan. Strong alignment with board recommendations signals investor confidence. Yet broker non-votes topped 2.8 million shares.
10-Q
Q2 FY2025 results
XBIOTECH INC. reported its Q2 FY2025 results ended June 30, 2025, but specific financial figures for revenue, profitability, or cash flows are not detailed in the provided filing excerpt. The document outlines standard 10-Q structure, including condensed consolidated financial statements and MD&A, yet lacks numerical data from primary statements or footnotes to analyze y/y or q/q deltas. Non-GAAP metrics are not disclosed in the 10-Q. Balance sheet and cash flow statements are referenced but not populated here. Liquidity details, such as cash or debt, remain unavailable. One key risk from Risk Factors involves intense competition in the biotech sector.
8-K
Board adds expertise
XBiotech bolstered its board on June 24, 2025, appointing Dr. Thomas Kündig, a dermatology expert with decades in immunotherapy research, to the Compensation Committee, and Craig Rademaker, a seasoned private equity leader overseeing $5 billion in assets, to the Audit Committee. These additions inject scientific depth and financial acumen into governance. New voices sharpen strategy. Terms end at the 2025 annual meeting.
IBIO
iBio, Inc.
2.06+0.23
QTTB
Q32 Bio Inc.
2.88-0.17
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
STTK
Shattuck Labs, Inc.
2.94-0.12
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05
XLO
Xilio Therapeutics, Inc.
0.65+0.00
XNCR
Xencor, Inc.
16.55-0.24
XRTX
XORTX Therapeutics Inc.
0.59-0.01
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03
ZURA
Zura Bio Limited
4.12+0.05